sale exceed our/street estim
days-adjust constant-curr basi sale grew
less bill day set dental driver out-performance
total knees/hip line think knee lower hip higher versu
estim offset higher sale higher opex invest gross margin
better ep us/street led lower interest expens
reiter guidanc growth knee/hip compani report
slightli sequenti though comp eas call manag
highlight continu confid manufactur suppli posit earli feedback
rosa robot knee launch on-going shift focu toward increas
reconstruct market hip/kne days-adjust growth trail
month basi jnj/syk/zbh market manag note
materi end-market chang quarter total compani price
higher europ posit rebat adjust
line jnj/syk note in-lin sequenti ortho price
note focu near-term remain debt paydown manag
focus stabil core busi rather busi develop
 right assum focu pick head
remind loss bone cement distribut contract impact sale
rosa comment flexibl rel purchas option rosa knee
assum includ discount implant volum compani price
robot dispos discount market howev rosa spine limit
roll-out also way look leverag approv spine brain
indic potenti custom
guidanc remind sale guidanc includ
estim fx headwind ep guidanc includ
oper margin guidanc gross margin benefit year
hedg gain one less sell day one free cash
flow target
estim sale remain ep
continu estim sale growth lower ep
assum less cash use toward debt paydown
oper incom estim increas use cash instead
would upsid estim
year price histori
manufactur
distribut orthoped dental
trauma product relat surgic
analyst certif import disclosur see disclosur
underli sale growth improv full year sale growth
free cash flow use paydown debt guidanc
sg leverag begin build signific impact yet
suppli chain effici work
trade discount large-cap peer
price-to-earnings key mileston look forward zimmer shift
focu improv suppli cost reduct initi
continu build-out special salesforc new
product launch led robot knee spine system
limit full launch key launch includ
persona cementless full launch underway revis
persona cementless on-going revis knee launch
launch rosa knee spine
quicker return full product suppli share recaptur
faster acceler busi outsid large-joint ortho
use growth enhanc tuck-in
neg respons fda warn letter respons
slower expect hip/kne market growth
greater expect impact competitor rollout
price target driven blend discount cash flow compar pe analysi dcf use weight
averag cost capit wacc termin growth rate estim ebitda target impli p/
 multipl ep
risk price target includ wors expect price pressur key market declin procedur macro headwind
slower expect product suppli recoveri
stock price compani mention report
